Kennedy brings seven years of public company CFO experience
BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that Keith Kennedy, the Company’s Chief Operating Officer (COO), will also assume the responsibilities of Chief Financial Officer (CFO) and oversee the Company’s finance organization effective February 26, 2026.
Kennedy brings to CareDx over 20 years of experience and executive leadership in healthcare including global diagnostics, biopharma services, and contract development and manufacturing organization (CDMO). Kennedy has served as our Chief Operating Officer since September 2024. Prior to joining us, Kennedy served as CFO at PharmaLogic Holdings Corp from April 2022 to September 2024. At Veracyte, Kennedy served in various roles from December 2016 to May 2021, including as COO, CFO, and Secretary. Kennedy also held key executive positions at MCG Capital Corporation and GE Capital. He served as an Officer in the U.S. Air Force. Kennedy received a B.S. in Accounting with high distinction from Indiana University and an M.B.A. from the College of William & Mary. Kennedy is a Chartered Financial Analyst and Certified Public Accountant.
Nathan Smith announced on the company’s quarterly earnings call that he will be stepping down from his role as CFO.
About CareDx
CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company’s integrated solutions include non‑invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics‑based information for transplant patients. For more information, please visit www.caredx.com.
Forward Looking Statements
This press release includes forward-looking statements related to CareDx, Inc. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including general economic and market factors and other risks discussed in CareDx’s filings with the SEC, including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2025 to be filed by CareDx with the SEC on February 25, 2026, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
CareDx
Media Contacts
Natasha Moshirian Wagner
nwagner@caredx.com
Investor Relations
Caroline Corner
investor@caredx.com
